Trial Outcomes & Findings for Dietary Control Alone Versus Dietary Control Plus Use of Proton Pump Inhibitors to Treat Pediatric Hoarseness (NCT NCT00637416)

NCT ID: NCT00637416

Last Updated: 2017-01-23

Results Overview

Change measured using voice assessment protocol-Grade, Roughness, Breathiness, Asthenia, Strain (GRBAS).

Recruitment status

TERMINATED

Study phase

PHASE4

Target enrollment

9 participants

Primary outcome timeframe

3 months

Results posted on

2017-01-23

Participant Flow

Participant milestones

Participant milestones
Measure
Lansoprazole and Dietary Control
Lansoprazole and dietary control Lansoprazole: Lansoprazole 30 mg taken by mouth daily for 3 months
Placebo and Dietary Control
Dietary control and placebo Placebo: placebo taken by mouth daily for 3 months
Overall Study
STARTED
4
5
Overall Study
COMPLETED
3
3
Overall Study
NOT COMPLETED
1
2

Reasons for withdrawal

Reasons for withdrawal
Measure
Lansoprazole and Dietary Control
Lansoprazole and dietary control Lansoprazole: Lansoprazole 30 mg taken by mouth daily for 3 months
Placebo and Dietary Control
Dietary control and placebo Placebo: placebo taken by mouth daily for 3 months
Overall Study
Lost to Follow-up
1
1
Overall Study
Unable to take study drug
0
1

Baseline Characteristics

Dietary Control Alone Versus Dietary Control Plus Use of Proton Pump Inhibitors to Treat Pediatric Hoarseness

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Lansoprazole and Dietary Control
n=4 Participants
Lansoprazole and dietary control Lansoprazole: Lansoprazole 30 mg taken by mouth daily for 3 months
Placebo and Dietary Control
n=5 Participants
Dietary control and placebo Placebo: placebo taken by mouth daily for 3 months
Total
n=9 Participants
Total of all reporting groups
Age, Categorical
<=18 years
4 Participants
n=5 Participants
5 Participants
n=7 Participants
9 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Age, Categorical
>=65 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Gender
Female
2 Participants
n=5 Participants
2 Participants
n=7 Participants
4 Participants
n=5 Participants
Gender
Male
2 Participants
n=5 Participants
3 Participants
n=7 Participants
5 Participants
n=5 Participants
Region of Enrollment
United States
4 participants
n=5 Participants
5 participants
n=7 Participants
9 participants
n=5 Participants

PRIMARY outcome

Timeframe: 3 months

Population: Study was stopped early, data were not collected, and zero participants were analyzed.

Change measured using voice assessment protocol-Grade, Roughness, Breathiness, Asthenia, Strain (GRBAS).

Outcome measures

Outcome data not reported

Adverse Events

Lansoprazole and Dietary Control

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Placebo and Dietary Control

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Director, ENT Clinical Research

University of Kansas Medical Center

Phone: (913) 588-7154

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place